Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT04866017) enrolled 63 people across three groups. Twenty-two participants received a combination of two immunotherapy medicines — ociperlimab and tislelizumab — alongside a standard radiation-and-chemotherapy treatment (called concurrent chemoradiotherapy, or cCRT). Nineteen participants received tislelizumab plus cCRT, and 22 received cCRT followed by a different immunotherapy medicine called durvalumab. The trial was set up to measure how long people went without their cancer growing or spreading (called progression-free survival), as well as several other measures such as overall survival (how long people lived), how many people's cancer shrank or disappeared, and how long any such response lasted. The reported data shows that no numerical results were submitted for any of the outcome measures — including the primary measure of progression-free survival and all secondary measures such as overall survival, response rate, duration of response, time to distant spread, and longer-term progression-free survival. In other words, the actual figures for these outcomes were not reported in the structured data on ClinicalTrials.gov. It is also worth noting that zero participants across all three groups are recorded as having "completed" the study, with all participants listed under "not completed," though the reasons for this were not detailed in the data provided. Because no outcome numbers have been submitted, it is not possible to describe what the trial found in terms of measurable results. The reported data shows only that the trial ran, that participants were treated, and that result figures are currently absent from the public record on ClinicalTrials.gov. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Lung Cancer Trial, Terminated
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You must be 18 years old or older (or meet the legal age of consent in your country) at the time of signing the consent form.
- You must have been diagnosed with a specific type of lung cancer (non-small cell lung cancer, Stage III) that cannot be removed by surgery, confirmed through a tissue or cell sample.
- You must have already completed at least 2 rounds of a platinum-based chemotherapy given at the same time as radiation therapy.
- Your lung cancer must not have gotten worse during or after that combined chemotherapy and radiation treatment.
- You must be generally well enough to carry out daily activities, with only mild limitations at most (confirm with trial site).
- Your liver, kidneys, and other organs must be working well enough as shown by blood tests (confirm with trial site).
- You must be willing to provide a stored tumor tissue sample, or have a new tissue sample taken before treatment if no stored sample is available, so researchers can test it.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have previously received certain immunotherapy drugs that target specific immune system pathways, such as anti-PD-1 or anti-PD-L1 treatments (confirm with trial site).
- Your lung cancer has certain specific gene mutations or changes, including EGFR, ALK, ROS1, or RET (confirm with trial site).
- You received any other cancer treatments beyond the combined chemotherapy and radiation therapy described above.
- You are still experiencing side effects of Grade 3 or higher from your previous chemotherapy and radiation treatment (confirm with trial site).
- You have an active autoimmune disease, or a history of one that could come back.
- You have needed to take moderate-to-high doses of steroid medications or other immune-suppressing drugs within the last 14 days before starting the trial.
- You have had an active infection requiring antibiotic, antifungal, or antiviral treatment within the last 14 days — though ongoing antiviral treatment for chronic hepatitis B or C is allowed.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 7 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Progression-Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)
Other options
Data last synced from ClinicalTrials.gov: 1 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.